Bright Minds to Seek FDA Clarification and Refine Study
Bright Minds Biosciences plans to request clarification from the FDA and refine its study according to the agency’s recommendations.
Related stories
Sigma Lithium to Refinance Senior Debt and Extend Maturities to 2031
Sigma Lithium says net proceeds will refinance its senior secured debt in full with Synergy Capital and extend its debt maturity profile to 2031.
L impact | EQUITY | Nov 02, 2026, 02:41 PM UTC
IDBI Bank Employees Begin Two-Day Strike Over Planned Privatisation
IDBI Bank employees began a two-day nationwide strike Monday against the planned privatisation and proposed sale to Fairfax Financial Holdings. More than 10,000 staff across over 2
L impact | EQUITY | Nov 02, 2026, 02:41 PM UTC
Tempus AI shares rise 6.2% after Q3 profit
M impact | EQUITY | Nov 02, 2026, 02:40 PM UTC
Texas Instruments, Analog Devices and Qualcomm Rise
Texas Instruments is up 1.9%, Analog Devices 2.1% and Qualcomm 2.6%.
M impact | EQUITY | Nov 02, 2026, 02:40 PM UTC
Nvidia Shares Rise 1.5%; SK Hynix ADRs Gain 3.3%
M impact | EQUITY | Nov 02, 2026, 02:40 PM UTC
Anthropic: Granted Google the option to buy up to $10b in Class N stock $GOOGL
L impact | EQUITY | Nov 02, 2026, 02:39 PM UTC